MCID: BNC003
MIFTS: 58

Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases

Aliases & Classifications for Bone Cancer

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 43 15
Bone Carcinoma 12 15 73
Malignant Bone Neoplasm 12 73
Bone Neoplasms 44 73
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 73
Osteogenic Neoplasm 73
Ca - Bone Cancer 12
Neoplasm of Bone 12
Bone Neoplasm 12
Osseous Tumor 12
Bone Tumour 12

Classifications:



External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 44 D001859
NCIt 50 C9343 C36082

Summaries for Bone Cancer

MedlinePlus : 43 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as bone carcinoma, is related to ewing sarcoma and villonodular synovitis, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are TNFR1 Pathway and Development Endothelin-1/EDNRA signaling. The drugs Quadramet and Xgeva have been mentioned in the context of this disorder. Affiliated tissues include bone, spinal cord and dorsal root ganglion, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A bone cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

Related Diseases for Bone Cancer

Diseases in the Bone Cancer family:

Bone Benign Neoplasm Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 31.5 BMI1 CYCS EWSR1 IL6 MMP9
2 villonodular synovitis 29.8 MMP9 TNFSF11
3 giant cell tumor 29.6 MMP9 TNFRSF11A TNFSF11
4 bone disease 29.5 COL1A1 IL6 TNFRSF11A TNFSF11
5 bone resorption disease 29.3 COL1A1 ESR1 IL6 TNFRSF11A TNFSF11 TRPV1
6 osteoporosis 29.2 CNR1 COL1A1 ESR1 IL6 TNFRSF11A TNFSF11
7 chest wall bone cancer 12.2
8 primary bone cancer 12.1
9 bone marrow cancer 11.3
10 maxillary cancer 11.0
11 adamantinoma of long bones 10.9
12 osteogenic sarcoma 10.9
13 aneurysmal bone cysts 10.9
14 bone squamous cell carcinoma 10.8
15 chondrosarcoma 10.8
16 multiple enchondromatosis, maffucci type 10.8
17 bone fracture 10.8
18 long bones of lower limb cancer 10.8
19 jaw cancer 10.8
20 orbital cancer 10.8
21 bone giant cell tumor 10.8
22 sternum cancer 10.8
23 paget's disease of bone 10.8
24 femoral cancer 10.8
25 bone lymphoma 10.8
26 osteoblastoma 10.4
27 polyarticular onset juvenile idiopathic arthritis 10.3 TNFRSF11A TNFSF11
28 breast leiomyosarcoma 10.3 TNFRSF11A TNFSF11
29 pain agnosia 10.3 CNR1 PDYN TRPV1
30 hemophilic arthropathy 10.3 TNFRSF11A TNFSF11
31 agnosia 10.3 CNR1 PDYN TRPV1
32 cyclic vomiting syndrome 10.3 CNR1 IL6
33 osteopetrosis, autosomal recessive 7 10.3 TNFRSF11A TNFSF11
34 specific developmental disorder 10.3 CNR1 PDYN TRPV1
35 paget disease of bone 5, juvenile-onset 10.3 TNFRSF11A TNFSF11
36 periapical periodontitis 10.2 IL6 TNFRSF11A TNFSF11
37 root resorption 10.2 P2RX7 TNFRSF11A TNFSF11
38 oslam syndrome 10.2
39 malignant neoplasm of short bones of lower limb 10.2
40 mandibular cancer 10.2
41 ameloblastic carcinoma 10.2
42 periodontitis, chronic 10.2 IL6 TNFSF11
43 disease of mental health 10.2 CNR1 PDYN TRPV1
44 drug dependence 10.2 CNR1 PDYN PENK
45 osteoporotic fracture 10.2 COL1A1 ESR1 IL6
46 autoimmune disease of central nervous system 10.2 CCL2 IL6 TRPV1
47 mouth disease 10.2 IL6 TNFSF11 TRPV1
48 autoimmune disease of the nervous system 10.2 CCL2 IL6 TRPV1
49 adenomyosis 10.2 ESR1 MMP9 TRPV1
50 cystitis 10.2 CCL2 IL6 TRPV1

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer

Symptoms & Phenotypes for Bone Cancer

UMLS symptoms related to Bone Cancer:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 ATF3 CNR1 COL1A1 CYCS ESR1 IL6
2 growth/size/body region MP:0005378 10.29 ATF3 CNR1 COL1A1 CYCS ESR1 IL6
3 immune system MP:0005387 10.22 ATF3 CCL2 COL1A1 CYCS ESR1 IL6
4 homeostasis/metabolism MP:0005376 10.21 ATF3 CNR1 COL1A1 ESR1 IL6 MMP9
5 cardiovascular system MP:0005385 10.16 COL1A1 CYCS ESR1 IL6 MMP9 MTAP
6 hematopoietic system MP:0005397 10.16 ATF3 COL1A1 CYCS ESR1 IL6 MMP9
7 integument MP:0010771 10.15 ATF3 CNR1 COL1A1 ESR1 IL6 MMP9
8 adipose tissue MP:0005375 10.08 ATF3 CNR1 COL1A1 ESR1 IL6 PDYN
9 digestive/alimentary MP:0005381 10.04 CNR1 COL1A1 ESR1 IL6 MMP9 PDYN
10 limbs/digits/tail MP:0005371 9.87 COL1A1 ESR1 MMP9 P2RX7 PENK TNFRSF11A
11 neoplasm MP:0002006 9.86 ATF3 COL1A1 ESR1 IL6 MMP9 TNFRSF11A
12 no phenotypic analysis MP:0003012 9.81 ATF3 CNR1 COL1A1 ESR1 PDYN PENK
13 respiratory system MP:0005388 9.56 ATF3 COL1A1 ESR1 IL6 MMP9 MTAP
14 skeleton MP:0005390 9.36 CNR1 COL1A1 CYCS ESR1 IL6 MMP9

Drugs & Therapeutics for Bone Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Quadramet 18 SAMARIUM SM-153 LEXIDRONAM PENTASODIUM DuPont Merck Pharmaceutical Company March 1997
2
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
3
Xofigo 18 49 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
4
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 463)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
2
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
3
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
4
Zoledronic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 118072-93-8 68740
5
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
6
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
7
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
8
Radium Ra 223 dichloride Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 444811-40-9
9
Lithium carbonate Approved Phase 4 554-13-2
10
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
11
Dalteparin Approved Phase 4,Not Applicable 9005-49-6
12
Enoxaparin Approved Phase 4 9005-49-6 772
13
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
14
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
15
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 1406-16-2
16 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Hydrocortisone 17-butyrate 21-propionate Phase 4
19 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
20 Hydrocortisone-17-butyrate Phase 4
21 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Anesthetics Phase 4,Phase 3,Phase 1,Not Applicable
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Cortisol succinate Phase 4
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
27 Diphosphonates Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
29 Calcium, Dietary Phase 4,Phase 1,Phase 2,Not Applicable
30 Vitamins Phase 4,Phase 2,Phase 1,Not Applicable
31 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
32 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
33 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
34 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Adrenergic Agents Phase 4,Not Applicable
37 Neurotransmitter Uptake Inhibitors Phase 4
38 Sympathomimetics Phase 4
39 Dopamine Uptake Inhibitors Phase 4
40 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
41 Dopamine Agents Phase 4,Phase 2
42 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
43 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Ibandronic acid Phase 4,Phase 3,Phase 2
45 Calciferol Phase 4,Phase 2,Phase 1
46 Central Nervous System Depressants Phase 4,Phase 3,Phase 1,Early Phase 1,Not Applicable
47 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
48 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
49 Antibodies, Monoclonal Phase 4,Phase 3,Phase 2,Phase 1
50 Cyclooxygenase Inhibitors Phase 4,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 769)
# Name Status NCT ID Phase Drugs
1 The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy Unknown status NCT02905916 Phase 4 PEG-rhG-CSF
2 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
3 Bioactive Glass Granules in Filling of Bone Defects Completed NCT01304121 Phase 4
4 Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases Completed NCT00434447 Phase 4 Zoledronic acid
5 A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer Completed NCT02553707 Phase 4 Ibandronate
6 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
7 FREE Study - Fracture Reduction Evaluation Completed NCT00211211 Phase 4
8 Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
9 Screening Non Small Cell Lung Cancer With Bone Metastasis and Efficacy and Safety Research of Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
10 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
11 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
12 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
13 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
14 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
15 Radium-223 Dichloride Long-term Follow-up Program Recruiting NCT02312960 Phase 4
16 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
17 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
18 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
19 A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer Terminated NCT00381095 Phase 4 Pregabalin;Placebo
20 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
21 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
22 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
23 Non-invasive Focal Therapy for Osteoid Osteoma Unknown status NCT02302651 Phase 2, Phase 3
24 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases Unknown status NCT01429493 Phase 2, Phase 3
25 F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets Unknown status NCT00882609 Phase 3
26 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
27 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
28 Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement Unknown status NCT01813240 Phase 2, Phase 3 Minocycline;placebo
29 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
30 Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy Completed NCT02711007 Phase 2, Phase 3 apatinib
31 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3 Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
32 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3 High Dose Methotrexate
33 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3 pre-surgical chemotherapy
34 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
35 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
36 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
37 A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
38 A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease Completed NCT02561039 Phase 3 Ibandronate
39 Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy Completed NCT00041665 Phase 3 Recombinant Human Keratinocyte Growth Factor
40 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
41 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
42 Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009 Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
43 Palliation: the Effect of Education on Pain Completed NCT01358539 Phase 3
44 Dexamethasone vs Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
45 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
46 Evaluation of Vertebroplasty Associated With Radiotherapy for Spine Metastases (EVAR) Completed NCT00267033 Phase 3
47 Palliative Radiotherapy for Bone Metastases: Single Versus Multiple Fractions. Completed NCT00858741 Phase 3
48 Optimization of Radiotherapy in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
49 Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
50 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: bone neoplasms

Genetic Tests for Bone Cancer

Anatomical Context for Bone Cancer

MalaCards organs/tissues related to Bone Cancer:

41
Bone, Spinal Cord, Dorsal Root Ganglion, Lung, Prostate, Liver, Thyroid

Publications for Bone Cancer

Articles related to Bone Cancer:

(show top 50) (show all 493)
# Title Authors Year
1
Suppression of HDAC2 in Spinal Cord Alleviates Mechanical Hyperalgesia and Restores KCC2 Expression in a Rat Model of Bone Cancer Pain. ( 29482000 )
2018
2
Adverse events associated with aprepitant pediatric bone cancer patients. ( 29409391 )
2018
3
A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain. ( 29371114 )
2018
4
Socio-economic patterning in early mortality of patients aged 0-49 years diagnosed with primary bone cancer in Great Britain, 1985-2008. ( 29414632 )
2018
5
IL-18 Contributes to Bone Cancer Pain by Regulating Glia Cells and Neuron Interaction. ( 29079540 )
2018
6
Longitudinal resting-state fMRI in a mouse model of metastatic bone cancer reveals distinct functional reorganizations along a developing chronic pain state. ( 29319607 )
2018
7
Expression of BDNF in dorsal root ganglion of rats with bone cancer pain and its effect on pain behavior. ( 29504577 )
2018
8
Inhibition of Connexin 43 and Phosphorylated NR2B in Spinal Astrocytes Attenuates Bone Cancer Pain in Mice. ( 29867362 )
2018
9
Spinal PKC activation - Induced neuronal HMGB1 translocation contributes to hyperalgesia in a bone cancer pain model in rats. ( 29428215 )
2018
10
CORR InsightsAr: Can Augmented Reality Be Helpful in Pelvic Bone Cancer Surgery? An In Vitro Study. ( 29762155 )
2018
11
Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. ( 29127069 )
2018
12
Hedgehog signaling contributes to bone cancer pain by regulating sensory neuron excitability in rats. ( 29607715 )
2018
13
Activation of ventral tegmental area dopaminergic neurons reverses pathological allodynia resulting from nerve injury or bone cancer. ( 29357732 )
2018
14
Electrical peripheral nerve stimulation relieves bone cancer pain by inducing Arc protein expression in the spinal cord dorsal horn. ( 29606887 )
2018
15
Neuronal complement cascade drives bone cancer pain via C3R mediated microglial activation. ( 29909203 )
2018
16
Dehydrocorydaline attenuates bone cancer pain by shifting microglial M1/M2 polarization toward the M2 phenotype. ( 29882480 )
2018
17
<sup>18</sup>F-Fluoride PET/CT and <sup>99m</sup>Tc-MDP SPECT/CT can detect bone cancer at early stage in rodents. ( 29778807 )
2018
18
Preconditioning with hydrogen sulfide prevents bone cancer pain in rats through a proliferator-activated receptor gamma/p38/Jun N-terminal kinase pathway. ( 29096563 )
2018
19
Blockage of spinal endothelin A receptors attenuates bone cancer pain via regulation of the Akt/ERK signaling pathway in mice. ( 29395120 )
2018
20
Health professional perceptions of communicating with adolescents and young adults about bone cancer clinical trial participation. ( 29978324 )
2018
21
A new method for selecting auricle positions in skull base reconstruction for temporal bone cancer. ( 29574745 )
2018
22
Fluoridation and county-level secondary bone cancer among cancer patients 18 years or older in New York State. ( 30109528 )
2018
23
Activation of the P2X7 receptor in midbrain periaqueductal gray participates in the analgesic effect of tramadol in bone cancer pain rats. ( 30198382 )
2018
24
Bone Cancer: Diagnosis and Treatment Principles. ( 30215968 )
2018
25
Bone Cancer. ( 30215985 )
2018
26
Bone morphogenetic protein and activin membrane-bound inhibitor suppress bone cancer progression in MG63 and SAOS cells via regulation of the TGF-β-induced EMT signaling pathway. ( 30250579 )
2018
27
In vitro evaluation of a biomaterial-based anticancer drug delivery system as an alternative to conventional post-surgery bone cancer treatment. ( 30274043 )
2018
28
Iodine-125 seed implantation combined with arterial chemoembolization therapy for pain palliation in metastatic bone cancer: a retrospective study. ( 30296196 )
2018
29
Bone-Cancer Assessment and Destruction Pattern Analysis in Long-Bone X-ray Image. ( 30367308 )
2018
30
Decitabine attenuates nociceptive behavior in a murine model of bone cancer pain. ( 30422869 )
2018
31
Upregulation of Spinal Voltage-Dependent Anion Channel 1 Contributes to Bone Cancer Pain Hypersensitivity in Rats. ( 29196874 )
2017
32
STAT1 as a downstream mediator of ERK signaling contributes to bone cancer pain by regulating MHC II expression in spinal microglia. ( 27742579 )
2017
33
Teniposide ameliorates bone cancer nociception in rats via the P2X7 receptor. ( 28825192 )
2017
34
Effect of alkylaminophenols on growth inhibition and apoptosis of bone cancer cells. ( 28728976 )
2017
35
Normalizing GDNF expression in the spinal cord alleviates cutaneous hyperalgesia but not ongoing pain in a rat model of bone cancer pain. ( 27716965 )
2017
36
Recombinant protein transduction domain-Cu/Zn superoxide dismutase alleviates bone cancer pain via peroxiredoxin 4 modulation and antioxidation. ( 28391978 )
2017
37
The Molecular Genetic Expression as a Novel Biomarker in the Evaluation and Monitoring of Patients With Osteosarcoma-Subtype Bone Cancer Disease. ( 28425009 )
2017
38
Resveratrol attenuates bone cancer pain through regulating the expression levels of ASIC3 and activating cell autophagy. ( 29036449 )
2017
39
Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain. ( 28286408 )
2017
40
Bone cancer: Is the osteosarcoma genome targetable? ( 28776583 )
2017
41
Efficacy and mechanism of action of etanercept in bone cancer pain. ( 29441991 )
2017
42
Bindarit Attenuates Pain and Cancer-Related Inflammation by Influencing Myeloid Cells in a Model of Bone Cancer. ( 29234825 )
2017
43
Morin Suppresses Astrocyte Activation and Regulates Cytokine Release in Bone Cancer Pain Rat Models. ( 28618070 )
2017
44
Hyperthermia effect and antibacterial efficacy of Fe(3+) /Co(2+) co-substitutions in I^-Ca3 (PO4 )2 for bone cancer and defect therapy. ( 28661574 )
2017
45
Plasma-induced selectivity in bone cancer cells death. ( 28571751 )
2017
46
Multi-target treatment of bone cancer pain using synergistic combinations of pharmacological compounds in experimental animals. ( 28850433 )
2017
47
The analgesic effects of triptolide in the bone cancer pain rats via inhibiting the upregulation of HDACs in spinal glial cells. ( 29096654 )
2017
48
Retraction Statement: CXCL12/CXCR4 chemokine signaling in spinal glia induces pain hypersensitivity through MAPKs-mediated neuroinflammation in bone cancer rats. ( 28417467 )
2017
49
Bufalin attenuates cancer-induced pain and bone destruction in a model of bone cancer. ( 28840279 )
2017
50
Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. ( 28565880 )
2017

Variations for Bone Cancer

Copy number variations for Bone Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer

Expression for Bone Cancer

Search GEO for disease gene expression data for Bone Cancer.

Pathways for Bone Cancer

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.48 ATF3 CCL2 CYCS IL6 MMP9 TNFRSF11A
2
Show member pathways
12.39 COL1A1 CYCS TNFRSF11A TNFSF11 TRPV1
3 11.94 BMI1 EWSR1 IL6 MMP9
4 11.77 CCL2 IL6 MMP9
5 11.74 BMI1 COL1A1 IL6
6 11.68 CCL2 COL1A1 IL6
7 11.64 CCL2 IL6 MMP9 PDYN
8 11.48 CCL2 IL6 MMP9
9 11.41 CCL2 IL6 MMP9
10 11.21 CCL2 IL6 TNFRSF11A TNFSF11
11 11.03 CCL2 IL6 MMP9
12 10.78 CCL2 COL1A1 IL6 PENK TNFSF11
13 10.73 TNFRSF11A TNFSF11
14 10.64 COL1A1 TNFSF11
15 10.58 COL1A1 IL6 TNFRSF11A TNFSF11

GO Terms for Bone Cancer

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 ATF3 IL6 P2RX7 RLN2 TNFSF11
2 positive regulation of apoptotic process GO:0043065 9.89 CNR1 IL6 MMP9 P2RX7 TRPV1
3 cytokine-mediated signaling pathway GO:0019221 9.87 CCL2 IL6 MMP9 TNFSF11
4 regulation of signaling receptor activity GO:0010469 9.85 CCL2 IL6 PDYN PENK RLN2 TNFSF11
5 response to lipopolysaccharide GO:0032496 9.83 CNR1 P2RX7 PENK TNFRSF11A
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.78 IL6 TNFRSF11A TNFSF11 TRIM14
7 response to bacterium GO:0009617 9.77 CCL2 P2RX7 PENK
8 response to estradiol GO:0032355 9.76 COL1A1 ESR1 PENK
9 osteoblast differentiation GO:0001649 9.75 COL1A1 MRC2 PENK
10 ossification GO:0001503 9.62 COL1A1 MMP9 TNFRSF11A TNFSF11
11 negative regulation of bone resorption GO:0045779 9.56 IL6 P2RX7
12 PERK-mediated unfolded protein response GO:0036499 9.55 ATF3 CCL2
13 tooth eruption GO:0044691 9.51 COL1A1 TNFSF11
14 TNFSF11-mediated signaling pathway GO:0071847 9.46 TNFRSF11A TNFSF11
15 sensory perception of pain GO:0019233 9.46 CNR1 P2RX7 PENK TRPV1
16 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.43 TNFRSF11A TNFSF11
17 mammary gland alveolus development GO:0060749 9.43 ESR1 TNFRSF11A TNFSF11
18 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.4 TNFRSF11A TNFSF11
19 monocyte chemotaxis GO:0002548 9.26 CCL2 IL6 TNFRSF11A TNFSF11
20 positive regulation of DNA-binding transcription factor activity GO:0051091 9.02 ESR1 IL6 TNFRSF11A TNFSF11 TRIM14

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 opioid peptide activity GO:0001515 8.62 PDYN PENK

Sources for Bone Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....